top of page

CMML

HGEN-AACR-Posters-03-21-2023.jpg

PREACH-M Trial Update

Humanigen was honored to present progress from the PREACH-M trial evaluating lenzilumab in CMML today at AACR in Orlando, FL. #HGEN

Blood-CMML-Phase-1-Study-01.jpg
Blood-CMML-Article-01.jpg

Blood

Phase 1 study of lenzilumab, a recombinant
anti–human GM-CSF antibody, for chronic myelomonocytic leukemia

Blood

A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor
(anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML)

bottom of page